Article
Clinicopathological factors affecting progression-free survival of patients with previously treated advanced non-small cell lung cancer after S-1 therapy with or without bevacizumab.
Anticancer research - 1 Dec 2014
Masago Katsuhiro, Fujita Shiro, Hata Akito, Kaji Reiko, Ohtsuka Kyoko, Okuda Chiyuki, Takeshita Jumpei, Katakami Nobuyuki
Abstract excerpt
OBJECTIVES: The aim of the present study was to analyze factors that affect progression-free survival (PFS) of patients with previously treated advanced non-small cell lung cancer (NSCLC) after S-1 therapy, in particular epidermal growth factor receptor (EGFR) mutation status. PATIENTS AND METHODS: Between October 2009 and June 2013, 56 patients with advanced NSCLC were analyzed for EGFR somatic mutations and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.